TITLE

Amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive black or nonblack patients: COMMENTARY

AUTHOR(S)
Rosenberg, Mark; Jain, Meera
PUB. DATE
November 2005
SOURCE
ACP Journal Club;Nov/Dec2005, Vol. 143 Issue 3, p63
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article comments on a clinical study according to which amlodipine or lisinopril was not better than chlorthalidone for reducing CVD risk in hypertensive black or nonblack patients. In this planned substudy of the ALLHAT trial, researchers examined whether CVD outcomes differed between black and nonblack patients who were started on 1 of 3 different classes of antihypertensive agents. In this trial, black patients in the lisinopril group had increased rates of stroke, CHD, and combined CVD. Despite equivalent blood pressure-lowering in patients treated with amlodipine and chlorthalidone, fewer patients of either race developed HF while taking chlorthalidone.
ACCESSION #
18925734

 

Related Articles

  • Inadequate Heart Disease Prevention in Europe in Spite of Medication Use. Kiefer, Dale // Life Extension;Jul2009, Vol. 15 Issue 7, p23 

    The article discusses a study on the inadequacy of heart disease prevention in spite of medications in Europe. The study found that levels of high blood pressure and abnormal high blood lipid levels remain high despite the use of antihypertensive and lipid-lowering drugs. Data of the study were...

  • Commentary. Rosenberg, Mark; Jain, Meera // Evidence Based Medicine;Dec2005, Vol. 10 Issue 6, p170 

    The article comments on the planned substudy of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial which examined whether cardiovascular disease outcomes differed between black and non-black patients. The patients were started on different classes of antihypertensive...

  • Commentary. Zornke, Kelly B. // Evidence Based Medicine;Apr2006, Vol. 11 Issue 2, p42 

    The article presents comments on the results of a study aiming to determine whether amlodipine plus perindopril is more effective than atenolol plus bendroflumethiazide for reducing cardiovascular outcomes in patients with cardiovascular diseases. Thiazide diuretics is the most appropriate first...

  • nadolol.  // Royal Society of Medicine: Medicines;2002, p381 

    The article presents information on the hypotensive agent nadolol. The drug can be used to control blood pressure and as a treatment to relieve symptoms and improve exercise tolerance. It is orally administered. It is available as an antihypertensive treatment in the form of compound...

  • Treatment of Acute Severe Hypertension: Current and Newer Agents. Varon, Joseph // Drugs;2008, Vol. 68 Issue 3, p283 

    Approximately 72 million people in the US experience hypertension. Worldwide, hypertension may affect as many as 1 billion people and be responsible for ≈7.1 million deaths per year. It is estimated that ≈1% of patients with hypertension will, at some point, develop...

  • SHORT CUTS. Tonks, Alison // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/22/2011, Vol. 342 Issue 7790, p196 

    This section discusses various studies related to medicine and medical care. One study, published in the "New England Journal of Medicine," found that genetic profiling causes little or no distress or anxiety on U.S. adults. Another study, which appeared in "Lancet," concluded that using...

  • Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension. Dahlöf, B.; Sever, P. S.; Poulter, N. R. // Evidence Based Medicine;Apr2006, Vol. 11 Issue 2, p42 

    The article focuses on the results of a study to determine whether amlodipine plus perindopril is more effective than atenolol plus bendroflumethiazide for reducing cardiovascular outcomes in patients with cardiovascular diseases. Amlodipine plus perindopril was better at reducing mortality,...

  • Efficacy, Safety, and Palatability of RACTAB® Formulation Amlodipine Orally Disintegrating Tablets. Fukui-Soubou, Mari; Terashima, Hirotaka; Kawashima, Kiyoshi; Utsunomiya, Osamu; Terada, Taichiroh // Drugs in R&D;2011, Vol. 11 Issue 4, p327 

    Objective: The aim of this study was to confirm the efficacy, safety, and expected palatability of amlodipine orally disintegrating tablets (ODT) [RACTAB® formulation (Towa, Osaka, Japan)]. We report the re-analyzed results of 1687 cases in clinical settings obtained through postmarketing...

  • Amlodipine/benazepril combo lowered CVD morbidity, mortality by 20.  // Endocrine Today;4/25/2008, Vol. 6 Issue 7, p1 

    The article reports on the results of the ACCOMPLISH trial which made use of combined amlodipine and benazepril. According to results presented by Dr. Kenneth A. Jamerson at the American College of Cardiology 57th Annual Scientific Sessions, a single-tablet form consisting of amlodipine and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics